American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 579.e1-579.e8 , December 2009

Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy

  • Ronit Calderon-Margalit, MD, MPH

      Affiliations

    • Cardiovascular Health Research Unit, University of Washington School of Public Health and Community Medicine, Seattle, WA
    • Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA
    • Corresponding Author InformationReprints: Ronit Calderon-Margalit, MD, University of Washington, Cardiovascular Health Research Unit, 1730 Minor Ave., Suite 1360, Seattle, WA 98101
    • ,
  • Chunfang Qiu, MD, MS

      Affiliations

    • Center for Perinatal Studies, Swedish Medical Center, Seattle, WA
    • ,
  • Asher Ornoy, MD

      Affiliations

    • Israeli Teratogen Information Service, Laboratory of Teratology, Hebrew University, Hadassah Medical School and Israeli Ministry of Health, Jerusalem, Israel
    • ,
  • David S. Siscovick, MD, MPH

      Affiliations

    • Cardiovascular Health Research Unit, University of Washington School of Public Health and Community Medicine, Seattle, WA
    • Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA
    • Department of Medicine, University of Washington, Seattle, WA
    • ,
  • Michelle A. Williams, ScD

      Affiliations

    • Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA
    • Center for Perinatal Studies, Swedish Medical Center, Seattle, WA

Received 8 December 2008 ,Revised 13 April 2009 ,Accepted 24 June 2009.

References 

  1. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62:863–870
  2. Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG. 2007;114:1055–1064
  3. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198:194;e1-5
  4. Stafford RS, MacDonald EA, Finkelstein SN. National Patterns of Medication Treatment for Depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry. 2001;3:232–235
  5. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol. 2005;4:465–475
  6. American College of Obstetricians and Gynecologists. Use of psychiatric medications during pregnancy and lactation: ACOG practice bulletin no. 92: clinical management guidelines for obstetrician-gynecologists, April 2008. (replaces practice bulletin no. 87) Obstet Gynecol. 2008;111:1001–1020
  7. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8:461–475
  8. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–2383
  9. Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119:52–59
  10. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84
  11. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371:261–269
  12. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015
  13. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312–316
  14. Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1203–1210
  15. Ornoy A, Arnon J, Shechtman S, Moerman L, Lukashova I. Is benzodiazepine use during pregnancy really teratogenic?. Reprod Toxicol. 1998;12:511–515
  16. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607–613
  17. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194:961–966
  18. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66:695–705
  19. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338–343
  20. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055–2061
  21. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301–308
  22. Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol. 2002;155:293–301
  23. Berle JO, Mykletun A, Daltveit AK, Rasmussen S, Holsten F, Dahl AA. Neonatal outcomes in offspring of women with anxiety and depression during pregnancy: a linkage study from the Nord-Trondelag Health study (HUNT) and Medical Birth Registry of Norway. Arch Womens Ment Health. 2005;8:181–189
  24. Glynn LM, Schetter CD, Hobel CJ, Sandman CA. Pattern of perceived stress and anxiety in pregnancy predicts preterm birth. Health Psychol. 2008;27:43–51
  25. Macleod J, Davey Smith G. Psychosocial factors and public health: a suitable case for treatment?. J Epidemiol Community Health. 2003;57:565–570
  26. Neutel CI, Patten SB. Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol. 1997;7:568–574

 This research was supported by awards from the National Institutes of Health (R01 HD-32562) and the Swedish Medical Center Foundation.

 Cite this article as: Calderon-Margalit R, Qiu C, Ornoy A, et al. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 2009;201:579.e1-8.

PII: S0002-9378(09)00705-4

doi: 10.1016/j.ajog.2009.06.061

American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 579.e1-579.e8 , December 2009

Article Tools

* Image Usage & Resolution